Pharma & Life Sciences Enterprise (201-1000 employees)

Medical Director at Enterprise

High Openness and Extraversion to lead medical-scientific strategy, represent the company before agencies, and build clinical positioning.

In enterprise pharma, multi-market regulatory complexity is the norm

10-15 year development cycles require genuine long-term vision

Pharmacovigilance and patient safety are non-delegable responsibilities

Ideal OCEAN+ Profile

Openness 80 Conscientiousness 90 Extraversion 76 Agreeableness 75 Emotional Stability 72 Structure & Rhythm 77
Ideal range
Openness
73 87

At enterprise companies (201-1000 employees), strategic scientific vision to design the evidence plan, lead advisory boards, and anticipate the medical landscape that will impact the portfolio

Conscientiousness
83 97

At enterprise companies (201-1000 employees), rigor in validating shared medical information, compliance with reporting obligations, and quality of the evidence strategy

Extraversion
69 83

At enterprise companies (201-1000 employees), executive presence in the C-suite, leadership of medical teams, and representation of the company before KOLs, agencies, and academia

Agreeableness
68 82

At enterprise companies (201-1000 employees), cross-functional influence over commercial, regulatory, and access teams to align medical strategy with business needs

Emotional Stability
65 79

At enterprise companies (201-1000 employees), handling safety crises, public scientific controversies, and business performance pressure that demand difficult medical-ethical decisions

Structure & Rhythm
68 85

At enterprise companies (201-1000 employees), the Medical Director alternates between medical process governance and scientific exploration; needs comfort with regulatory frameworks without structure preventing adjustments to the evidence plan when the clinical landscape shifts

Strengths and Red Flags

Strengths

  • Design of clinical evidence strategy that positions the portfolio in treatment guidelines
  • Scientific representation of the company before KOLs, agencies, and public health bodies
  • Managing product portfolios across multiple development and commercialization phases
  • Robust regulatory compliance with FDA, EMA, and local health authorities

Red Flags

  • Subordinating scientific objectivity to commercial business pressures
  • Disconnection from the real clinical environment, generating medical strategies that physicians do not adopt
  • Paralysis in the face of complex multi-product, multi-phase portfolios
  • Internal bureaucracy that delays go/no-go pipeline decisions

Interview Questions

Describe the most complex evidence strategy you designed. How did you balance scientific needs with the business's timelines and resources?

Evaluates: Strategic Openness and ability to balance science with business

The commercial team wants to position a subgroup finding that is statistically significant but clinically questionable. What position do you take and how do you communicate it internally?

Evaluates: Conscientiousness and medical-scientific integrity under commercial pressure

How did you manage a multi-product portfolio across different development phases?

Evaluates: Systemic vision and prioritization capacity at scale

How did you coordinate a multi-market regulatory registration process?

Evaluates: Conscientiousness and coordination in highly complex environments

More about Medical Director

Career path, personality archetypes and similar roles in the full profile.

This Role in Other Contexts

You're hiring a Medical Director at Enterprise (201-1000 employees). Is your company ready?

This profile describes who to look for. The Talent Diagnostic measures the other half: how ready your organization is for that person to perform. Free, no signup.

20 statements · 5 min · no card